Study shows Idylla EGFR mutation test is viable alternative to NGS lung cancer tests
Biocartis Group’s study has demonstrated that Idylla EGFR mutation test is a viable alternative to next generation sequencing…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
29 May 18
Biocartis Group’s study has demonstrated that Idylla EGFR mutation test is a viable alternative to next generation sequencing…
28 May 18
RenalGuard Solutions’s clinical trial showed that RenalGuard-guided diuretic therapy has improved breathing patterns and diuretic efficiency in acute…
28 May 18
Irish medical device company Neurent Medical has secured €9.3m in series A funding round led by Fountain Healthcare…
26 May 18
Getinge said that its intra-aortic balloon pump (IABP) has shown positive results in a pilot study evaluating the…
25 May 18
Foundation Medicine has collaborated with Merck for the development of companion diagnostic tests to be used with Keytruda…
25 May 18
The US Food and Drug Administration (FDA) has issued a Class I Recall of Abbott’s HeartMate 3 Left…
24 May 18
Medtronic’s SPYRAL HTN-ON MED study demonstrated that Symplicity Spyral renal denervation (RDN) system has reduced blood pressure in…
24 May 18
UK start-up Ultromics has secured £10m funding to advance the commercialization of artificial intelligence (AI) technology for the…
23 May 18
Providence Medical Technology has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its DTRAX…
22 May 18
Cerenovus, part of the Johnson & Johnson Medical Devices Companies, has secured 510(k) clearance from the US Food…